Dermata Therapeutics, Inc. (DRMA)
After hours:
| Previous close | 2.6100 |
| Open | 2.6999 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4500 - 2.6999 |
| 52-week range | 2.3400 - 30.3000 |
| Volume | |
| Avg. volume | 27,042 |
| Market cap | 1.394M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -13.0500 |
| Earnings date | 15 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
GlobeNewswirePresenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani
- GlobeNewswire
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
MIAMI, Feb. 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emerging Growth Conference on February 7 & 8, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa
ZacksDermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
